367 related articles for article (PubMed ID: 29323708)
1. MicroRNA501-5p induces p53 proteasome degradation through the activation of the mTOR/MDM2 pathway in ADPKD cells.
de Stephanis L; Mangolini A; Servello M; Harris PC; Dell'Atti L; Pinton P; Aguiari G
J Cell Physiol; 2018 Sep; 233(9):6911-6924. PubMed ID: 29323708
[TBL] [Abstract][Full Text] [Related]
2. Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells.
de Stephanis L; Bonon A; Varani K; Lanza G; Gafà R; Pinton P; Pema M; Somlo S; Boletta A; Aguiari G
Clin Exp Nephrol; 2017 Apr; 21(2):203-211. PubMed ID: 27278932
[TBL] [Abstract][Full Text] [Related]
3. MiR-15/16 complex targets p70S6 kinase 1 and controls cell proliferation in MDA-MB-231 breast cancer cells.
Janaki Ramaiah M; Lavanya A; Honarpisheh M; Zarea M; Bhadra U; Bhadra MP
Gene; 2014 Dec; 552(2):255-64. PubMed ID: 25261849
[TBL] [Abstract][Full Text] [Related]
4. The inhibition of MDM2 slows cell proliferation and activates apoptosis in ADPKD cell lines.
Patergnani S; Giattino A; Bianchi N; Giorgi C; Pinton P; Aguiari G
Biol Cell; 2023 Jan; 115(1):e2200037. PubMed ID: 36165233
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of microRNA501-5p affects the aggressiveness of clear cell renal carcinoma.
Mangolini A; Bonon A; Volinia S; Lanza G; Gambari R; Pinton P; Russo GR; Del Senno L; Dell'Atti L; Aguiari G
FEBS Open Bio; 2014; 4():952-65. PubMed ID: 25426415
[TBL] [Abstract][Full Text] [Related]
6. Berberine slows cell growth in autosomal dominant polycystic kidney disease cells.
Bonon A; Mangolini A; Pinton P; Del Senno L; Aguiari G
Biochem Biophys Res Commun; 2013 Nov; 441(3):668-74. PubMed ID: 24184483
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
[TBL] [Abstract][Full Text] [Related]
8. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
[TBL] [Abstract][Full Text] [Related]
9. Multidrug therapy for polycystic kidney disease: a review and perspective.
Aguiari G; Catizone L; Del Senno L
Am J Nephrol; 2013; 37(2):175-82. PubMed ID: 23428809
[TBL] [Abstract][Full Text] [Related]
10. MDM2 mediates fibroblast activation and renal tubulointerstitial fibrosis via a p53-independent pathway.
Ye C; Tang H; Zhao Z; Lei CT; You CQ; Zhang J; Gao P; He FF; Chen S; Wang YM; Zhang C; Su H
Am J Physiol Renal Physiol; 2017 Apr; 312(4):F760-F768. PubMed ID: 28100501
[TBL] [Abstract][Full Text] [Related]
11. mTOR inhibitors blunt the p53 response to nucleolar stress by regulating RPL11 and MDM2 levels.
Goudarzi KM; Nistér M; Lindström MS
Cancer Biol Ther; 2014; 15(11):1499-514. PubMed ID: 25482947
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis.
Li A; Fan S; Xu Y; Meng J; Shen X; Mao J; Zhang L; Zhang X; Moeckel G; Wu D; Wu G; Liang C
J Cell Mol Med; 2017 Aug; 21(8):1619-1635. PubMed ID: 28244683
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 Nef promotes ubiquitination and proteasomal degradation of p53 tumor suppressor protein by using E6AP.
Ali A; Farooqui SR; Rai J; Singh J; Kumar V; Mishra R; Banerjea AC
Biochem Biophys Res Commun; 2020 Sep; 529(4):1038-1044. PubMed ID: 32819562
[TBL] [Abstract][Full Text] [Related]
14. The degradation of p53 and its major E3 ligase Mdm2 is differentially dependent on the proteasomal ubiquitin receptor S5a.
Sparks A; Dayal S; Das J; Robertson P; Menendez S; Saville MK
Oncogene; 2014 Sep; 33(38):4685-96. PubMed ID: 24121268
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of histone deacetylase 2 induces p53-dependent survivin downregulation through MDM2 proteasomal degradation.
Seo SK; Hwang CS; Choe TB; Hong SI; Yi JY; Hwang SG; Lee HG; Oh ST; Lee YH; Park IC
Oncotarget; 2015 Sep; 6(28):26528-40. PubMed ID: 25605253
[TBL] [Abstract][Full Text] [Related]
16. mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53.
Jung SH; Hwang HJ; Kang D; Park HA; Lee HC; Jeong D; Lee K; Park HJ; Ko YG; Lee JS
Oncogene; 2019 Mar; 38(10):1639-1650. PubMed ID: 30337688
[TBL] [Abstract][Full Text] [Related]
17. Molecular Pathways Leading to Induction of Cell Death and Anti-Proliferative Properties by Tacrolimus and mTOR Inhibitors in Liver Cancer Cells.
Navarro-Villarán E; de la Cruz-Ojeda P; Contreras L; González R; Negrete M; Rodríguez-Hernández MA; Marín-Gómez LM; Álamo-Martínez JM; Calvo A; Gómez-Bravo MA; de la Cruz J; Padillo J; Muntané J
Cell Physiol Biochem; 2020 May; 54(3):457-473. PubMed ID: 32369692
[TBL] [Abstract][Full Text] [Related]
18. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
19. MDM2 regulates hypoxic hypoxia-inducible factor 1α stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner.
Joshi S; Singh AR; Durden DL
J Biol Chem; 2014 Aug; 289(33):22785-22797. PubMed ID: 24982421
[TBL] [Abstract][Full Text] [Related]
20. Differential Expression of MicroRNA-19b Promotes Proliferation of Cancer Stem Cells by Regulating the TSC1/mTOR Signaling Pathway in Multiple Myeloma.
Wang N; Liang X; Yu W; Zhou S; Fang M
Cell Physiol Biochem; 2018; 50(5):1804-1814. PubMed ID: 30396185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
